Immune checkpoint inhibitors in malignancy
Open Access
- 2 April 2019
- journal article
- research article
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 42 (2), 62-67
- https://doi.org/10.18773/austprescr.2019.012
Abstract
Immune checkpoint inhibitors help the immune system to see cancer cells that have adapted to escape detection.Keywords
This publication has 17 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaThe New England Journal of Medicine, 2017
- Emerging role of checkpoint blockade therapy in lymphomaTherapeutic Advances in Hematology, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- CTLA‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerationsCancer Medicine, 2015
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010